| CatalogCode: | NB110-57295 |
| ProductName: | p27 (Kip1) Antibody |
| Product Description: | Rabbit Monoclonal anti-p27 (Kip1) (Y236) |
| Clone: | Y236 |
| Clonality: | Monoclonal |
| Specificity: | A synthetic peptide corresponding to residues in the C-term of human p27(Kip1) was used as immunogen |
| CrossReactivity: | Reacts in human and rat. Does not react in mouse. Not tested in other species. |
| Packaging: | 0.1 ml Rabbit ascites. |
| Uses: | WB: 1:1,000IHC: 1:100-250ICC: 1:100-250Flow Cytometry: 1:40IP: 1:50 |
| Background: | p27(Kip1) is a cyclin-dependent kinase inhibitor involved in G1 arrest. p27(Kip1) binds to and inhibits cyclinE-Cdk2 complex, cyclinA-CDK2 and cyclinD1-CDK4 (1). p27(Kip1) is regulated by phosphorylation on serine 10 (S10) and threonine 187 (T187). Phosphorylation by CDK2 on T187 results in ubiquitylation and degradation of p27(Kip1) (2); while phosphorylation by hKIS on S10 signals the nuclear export to the cytoplasm (3). |
| Storage: | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Isotype: | IgG |
| Host_Name: | Rabbit |
| Buffer: | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, and 0.05% BSA. |
| ListPrice: | 325 |
| AppSummary: | FACS, IHC, IP, WB, ICC |
| SpeciesSummary: | Hu, Mu(-), Rt |
| ALTnames: | CDKN 1B antibody CDKN 4 antibody CDKN1B antibody CDKN4 antibody Cyclin Dependent Kinase Inhibitor 1B antibody Cyclin dependent kinase inhibitor p27 antibody KIP 1 antibody KIP1 antibody MEN1B antibody p27 Kip1 antibody P27KIP1 antibody |
| PackageSize: | 0.1 ml |
| GeneralRef: | 1. Polyak K., Lee M.-H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., Massague J.; Cell 78:59-66 (1994). 2. Carrano,A.C., Eytan,E., Hershko,A. and Pagano,M. (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1, 193-199 3. Rodier,G., Montagnoli,A., Di Marcotullio,L., Coulombe,P., Draetta,G.F., Pagano,M. and Meloche,S. (2001). EMBO J., 20, 6672-6682 |
order or
more information: | company product webpage |
| request information: |
|
|